BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BOSTON SCIENTIFIC CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $66.44B
- P/E (TTM)
- 18.2
- Dividend yield
- –
BOSTON SCIENTIFIC CORP revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $13.25B | $10.76B | $8.82B | $7.83B | $7.24B | $5.87B | $4.21B | $3.78B | $3.50B | $3.29B | 66.0% | +23.2% |
| MedSurg | $6.82B | $5.99B | $5.42B | $4.91B | $4.63B | $3.83B | $3.31B | $3.01B | $2.74B | $2.45B | 34.0% | +13.9% |
| Rhythm Management [Member] | – | – | – | – | – | – | – | – | $2.17B | $2.09B | – | – |
| Rhythm and Neuro [Member] | – | – | – | – | $3.29B | $2.75B | $3.14B | $3.04B | $2.81B | $2.65B | – | – |
| Global Urology (Uro) Reporting Unit [Member] | – | – | – | – | – | – | – | – | – | $1.07B | – | – |
| Neuromodulation | – | – | – | – | – | – | – | – | – | $574.00M | – | – |
| Global CRM Reporting Unit [Member] | – | – | – | – | – | – | – | – | – | $1.99B | – | – |
| Global Interventional Cardiology (IC) Reporting Unit [Member] | – | – | – | – | – | – | – | – | – | $2.52B | – | – |
| Global Electrophysiology (EP) Reporting Unit [Member] | – | – | – | – | – | – | – | – | – | $261.00M | – | – |
| Endoscopy | – | – | – | – | – | – | – | – | – | $1.57B | – | – |
| Peripheral Interventions [Member] | – | – | – | – | – | – | – | – | – | $1.09B | – | – |
| BSX Reportable Segments [Member] | – | – | – | – | $11.88B | $9.69B | $10.65B | $9.82B | $9.05B | – | – | – |
| Other Segments [Member] | – | – | – | – | – | – | $81.00M | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | – | – | – | – | – | – | $1.14B | $1.12B | $988.00M | $946.00M | – |
| MedSurg | – | – | – | – | – | – | $1.20B | $1.10B | $984.00M | $852.00M | – |
| Rhythm Management [Member] | – | – | – | – | – | – | – | – | $429.00M | $314.00M | – |
| Total allocated to reportable segments [Member] | – | – | – | $3.74B | $3.41B | $2.20B | $3.01B | $2.88B | $2.51B | $2.20B | – |
| Rhythm and Neuro [Member] | – | – | – | – | – | – | $666.00M | $655.00M | $537.00M | $402.00M | – |
| Specialty Pharmaceuticals [Member] | – | – | – | – | $4.00M | $143.00M | $56.00M | – | – | – | – |
| Other | – | – | – | -$60.00M | $4.00M | $143.00M | – | – | – | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $4.64B | $4.20B | $3.79B | – | – | – | – | – | – | – | 23.1% | +10.5% |
| Electrophysiology | $3.33B | $1.90B | $800.00M | $585.00M | $365.00M | $287.00M | – | – | – | – | 16.6% | +74.6% |
| Endoscopy | $2.92B | $2.69B | $2.48B | $2.22B | $2.14B | $1.78B | $1.89B | $1.76B | $1.62B | $1.44B | 14.5% | +8.5% |
| Urology | $2.71B | $2.20B | $1.96B | $1.77B | $1.58B | $1.29B | $1.41B | $1.25B | $1.12B | $1.01B | 13.5% | +23.1% |
| Cardiac Rhythm Management | $2.33B | $2.28B | $2.22B | $2.10B | $2.02B | $1.70B | – | – | – | – | 11.6% | +2.3% |
| Watchman | $1.96B | $1.52B | $1.27B | $1.02B | $829.00M | $324.00M | – | – | – | – | 9.8% | +29.2% |
| Neuromodulation | $1.20B | $1.11B | $976.00M | $917.00M | $909.00M | $761.00M | $873.00M | $779.00M | $635.00M | $556.00M | 6.0% | +8.4% |
| Interventional Oncology & Embolization | $996.00M | $856.00M | $736.00M | – | – | – | – | – | – | – | 5.0% | +16.4% |
| BTG Spec Pharma [Member] | – | – | – | – | – | – | $81.00M | – | – | – | – | – |
| Global Interventional Cardiology (IC) Reporting Unit [Member] | – | – | – | – | $3.04B | $2.30B | $2.82B | $2.59B | $2.42B | $2.28B | – | – |
| Global Electrophysiology (EP) Reporting Unit [Member] | – | – | – | – | $365.00M | $287.00M | $329.00M | $311.00M | $278.00M | $243.00M | – | – |
| Peripheral Interventions [Member] | – | $2.41B | $2.11B | $1.90B | $1.82B | $1.58B | $1.39B | $1.19B | $1.08B | $1.01B | – | – |
| Global CRM Reporting Unit [Member] | – | – | – | – | $2.02B | $1.70B | $1.94B | $1.95B | $1.90B | $1.85B | – | – |
| Specialty Pharmaceuticals [Member] | – | – | – | – | $13.00M | $219.00M | $81.00M | – | – | – | – | – |
| Cardiology [Member] | – | $8.34B | $6.71B | $5.93B | $5.42B | $4.29B | – | – | – | – | – | – |
| Interventional Cardiology & Vascular Therapies | – | $2.65B | $2.42B | $2.23B | $2.21B | $1.98B | – | – | – | – | – | – |
| Other | – | $0 | $0 | -$60.00M | $13.00M | $219.00M | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $12.86B | $10.21B | $8.43B | $7.63B | $6.91B | $5.70B | $6.17B | $5.54B | $5.16B | $4.76B | 64.1% | +26.0% |
| Int'l | $7.21B | $6.54B | $5.82B | $5.11B | $4.98B | $4.21B | $4.57B | $4.29B | $3.89B | $3.63B | 35.9% | +10.3% |
| Europe, Middle East and Africa | $3.45B | $3.23B | $2.86B | $2.53B | $2.52B | $2.10B | $2.26B | $2.18B | $1.94B | $1.80B | 17.2% | +6.9% |
| Asia-Pacific | $3.08B | $2.69B | $2.40B | $2.12B | $2.07B | $1.78B | $1.90B | $1.73B | $1.59B | $1.49B | 15.3% | +14.7% |
| Emerging Markets | $2.99B | $2.68B | $2.31B | $1.97B | $1.66B | $1.14B | $1.28B | $1.10B | $931.00M | $793.00M | 14.9% | +11.4% |
| Latin America and Canada | $678.00M | $624.00M | $560.00M | $469.00M | $386.00M | $307.00M | $395.00M | $383.00M | $358.00M | $333.00M | 3.4% | +8.7% |
| country_US excluding Other Net Sales | – | $10.21B | $8.43B | $7.63B | $6.90B | $5.51B | – | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Boston Scientific's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.